Retrospective Study
Copyright ©The Author(s) 2019.
World J Gastroenterol. Sep 28, 2019; 25(36): 5515-5529
Published online Sep 28, 2019. doi: 10.3748/wjg.v25.i36.5515
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Analysis of gamma-glutamyltransferase to aspartate aminotransferase ratio. A-C: Correlations of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase and aspartate aminotransferase (γ-GT/AST) with tumour size; D-F: Comparison of serum levels of PIVKA-II, AFP, and γ-GT/AST between early-stage hepatocellular carcinoma (HCC) patients, advanced HCC patients, and chronic hepatitis B patients. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Receiver-operating characteristic curves of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, the ratio of gamma-glutamyltransferase to aspartate aminotransferase, and their combinations in hepatocellular carcinoma patients. A and B: Receiver-operating characteristic (ROC) curves of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST), and their combinations in early-stage hepatocellular carcinoma (HCC) patients; chronic hepatitis B patients (CHB) served as controls; C and D: ROC curves of PIVKA-II, AFP, γ-GT/AST, and their combinations in HCC patients; CHB patients served as controls. ROC curve: Receiver-operating characteristic curve; PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Correlations of serum levels of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase with hepatitis B virus DNA. A-C: Comparisons of serum levels of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA+ and HBV DNA- hepatocellular carcinoma (HCC) patients; D-F: Comparisons of serum levels of PIVKA-II, AFP, and γ-GT/AST between HBV DNA+ and HBV DNA- chronic hepatitis B patients. G-I: Correlations of PIVKA-II, AFP, and γ-GT/AST with serum levels of HBV DNA in HBV DNA+ HCC patients. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Diagnostic value of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in hepatitis B virus DNA+ hepatocellular carcinoma patients. A-C: Comparisons of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP), and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA+ hepatocellular carcinoma (HCC) patients and HBV DNA+ chronic hepatitis B (CHB) patients; D: Receiver-operating characteristic (ROC) curves of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls; E: ROC curves of the combinations of PIVKA-II, AFP, and γ-GT/AST in HBV DNA+ HCC patients; HBV DNA+ CHB patients served as controls. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; ROC curve: Receiver-operating characteristic curve.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Diagnostic value of protein induced by vitamin K absence or antagonist II, alpha-fetoprotein, and the ratio of gamma-glutamyltransferase to aspartate aminotransferase in hepatitis B virus DNA- hepatocellular carcinoma patients. A-C: Comparisons of protein induced by vitamin K absence or antagonist II (PIVKA-II), alpha-fetoprotein (AFP) ,and the ratio of gamma-glutamyltransferase to aspartate aminotransferase (γ-GT/AST) between hepatitis B virus (HBV) DNA- hepatocellular carcinoma (HCC) patients and HBV DNA- chronic hepatitis B (CHB) patients; D: Receiver-operating characteristic (ROC) curves of PIVKA-II, AFP, and γ-GT/AST in HBV DNA- HCC patients; HBV DNA- CHB patients served as controls; E: ROC curves of the combinations of PIVKA-II, AFP, and γ-GT/AST in HBV DNA- HCC patients; HBV DNA- CHB patients served as controls. PIVKA-II: Protein induced by vitamin K absence or antagonist II; AFP: Alpha-fetoprotein; γ-GT/AST: The ratio of gamma-glutamyltransferase to aspartate aminotransferase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; CHB: Chronic hepatitis B; ROC curve: Receiver-operating characteristic curve.